In adult life, a subset of patients develop CTLN2, the most severe form, which can lead to premature death and is characterized by frequent attacks of hyperammonemia, liver steatosis, neuropsychiatric symptoms, and brain edema [5]. This evidence concerns the gene SLC25A13 and Hyperammonemia.